Skip to main content
    1. Congress Materials

    • International Congress on Neuromuscular Diseases (ICNMD), 2024

    Filter
    Close
    Filter
    ⁨⁨⁨⁨Keyword (eg, author, condition)
    Content type:
    Clear filters
    Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)
    Bril Vera, Grosskreutz Julian, Habib A. Ali, et al.
    Oral Presentation
    Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
    Habib A. Ali, Pascuzzi M. Robert, Vissing John, et al.
    Oral Presentation
    Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT
    James F. Howard Jr., Freimer Miriam, Genge Angela, et al.
    Oral Presentation
    Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study
    James F. Howard Jr., Desai Urvi, Govindarajan Raghav, et al.
    Poster
    Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
    M. Isabel Leite, Freimer Miriam, Genge Angela, et al.
    Poster